Skip to content
The Policy VaultThe Policy Vault

Gleevec — CareFirst (Caremark)

Hypereosinophilic Syndrome (HES)

Initial criteria

  • Diagnosis of HES or CEL

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months